Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie, Bristol-Myers get FDA nod for hep C treatments

[Reuters] – The U.S. Food and Drug Administration on Friday approved two treatments for less common forms of hepatitis C virus (HCV) infections. The regulator cleared AbbVie Inc’s Technivie, which targets HCV genotype . . . → Read More: Company Update: AbbVie Inc (NYSE:ABBV) – AbbVie, Bristol-Myers get FDA nod for hep C treatments Similar Articles: Stock Update (NYSE:ABBV): AbbVie hepatitis C cocktail succeeds in late-stage study Stock Update (NYSE:ABBV): AbbVie to Present at UBS Global Healthcare Conference Stock Update: AbbVie Inc (NYSE:ABBV) – AbbVie to Present at Barclays Global Health Care Conference